GNNSF (Genscript Biotech) Tariff Resilience Score: 5/10 (As of Jul. 12, 2026)


GNNSF Genscript Biotech Corp GNNSF
68 GF Score
Price $1.50
GF Value $2.81
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genscript Biotech Tariff Resilience Score?

Genscript Biotech GNNSF 68 Tariff Resilience Score is 5 as of Jul. 12, 2026. GuruFocus rates GNNSF with a GF Score™ of 68/100 and a GF Value™ of $2.81 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 1,370 Biotechnology companies, Genscript Biotech ranks better than 62.41% on this metric.

Genscript Biotech has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Genscript Biotech has Genscript Biotech, with a global supply chain, is moderately exposed to tariffs on biotech materials. While its innovative products offer some pricing power, supply chain disruptions could impact operations.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Genscript Biotech might have Average Resilient.

Genscript Biotech  (OTCPK:GNNSF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Genscript Biotech Tariff Resilience Score Related Terms

GNNSF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Genscript Biotech's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genscript Biotech Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's Tariff Resilience Score falls into.


GNNSF
68GF Score
Genscript Biotech Corp GNNSF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Genscript Biotech (GNNSF) has a Tariff Resilience Score of 5 as of Jul. 12, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Genscript Biotech ranks #515 out of 1370 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Genscript Biotech's Tariff Resilience Score too high?
Genscript Biotech's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Genscript Biotech's value of 5 is 25% above this industry median. Based on the distribution chart, Genscript Biotech ranks #515 out of 1370 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genscript Biotech has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #515 out of 1370 companies for Tariff Resilience Score. This puts Genscript Biotech in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Genscript Biotech's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genscript Biotech's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.81, compared to a current price of $1.50 — trading 46.6% below its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Genscript Biotech's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Tariff Resilience Score is 5 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genscript Biotech (GNNSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued. The current stock price of $1.50 is trading 46.6% below its estimated GF Value™ of $2.81. GuruFocus considers Genscript Biotech to be Significantly Undervalued.

Key valuation signals for GNNSF:

  • Tariff Resilience Score: 5
  • GF Value™: $2.81 vs. price of $1.50 (46.6% below fair value)
  • GF Score™: 68/100 with 4 warning signs
  • Industry Position: 25% above the Biotechnology median (#515 of 1370)

No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genscript Biotech Business Description

Other Exchanges 01548:Hong KongG51:Germany
Address 860 Centennial Avenue, Piscataway, NJ, USA, 08854
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
68GF Score

Get the complete analysis for GNNSF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.50
Price
$2.81
GF Value